Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Strong Q2 performance across our value drivers Growth1 Q2 Group sales +9%; H1 +3% Q2 IM sales +10%; H1 +5% Q2 Sandoz sales +5%; H1 -5% Productivity1 1 Innovation References 3 Iptacopan Ph2 studies met endpoints in PNH, IgAN, C3G (IA); Ph3 enrolling 177Lu-PSMA-617 Reduced mortality in patients with mCRPC; received FDA BTD Asciminib KymriahⓇ LeqvioⓇ ZolgensmaⓇ 2 ESG Submitted in US and EU for 3L CML ELARA pivotal study positive final readout in FL enabling submission Resubmitted new drug application to FDA (manufacturing CRL) Showed transformative efficacy in presymptomatic SMA 4 Q2 Group Core operating income +13%; H1 +2% Q2 IM core operating income +14%; H1 +6% Q2 IM core margin 37.3% (+1.3%pts cc); H1 36.8% Delivered 1bn antimalarial courses to patients in need since 1999 Advancing efforts on clinical trial diversity 10-year commitment to address root causes of health disparities All growth % in cc IM - Innovative Medicines division BTD Breakthrough Therapy designation 1. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 6 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation